24
total announcements
SHILPAMED.NS · 15 min delayed
Shilpa Medicare Limited
Shilpa Medicare Limited has informed the Exchange about a settlement agreement between its subsidiary, Shilpa Biologicals Pvt. Ltd, and Sartorius Stedim India Pvt. Ltd. for a payment of Rs. 9,00,00,000 to settle a dispute.
Shilpa Medicare Limited
Shilpa Medicare Limited has informed the Exchange about Copy of Newspaper Publication regarding shifting of Registered office.
Shilpa Medicare Limited
Shilpa Medicare Limited, through its material subsidiary Shilpa Biologicals Private Ltd, has commissioned a state-of-the-art Antibody-Drug Conjugate (ADC) GMP Manufacturing Facility. This facility is one of India's few integrated sites for ADC Drug Substance production, designed to meet global regulatory standards. Leveraging Shilpa's 25-year expertise in highly potent compounds, this expansion strategically positions the company as a key Contract Development and Manufacturing Organization (CDMO) partner for global biotech and pharmaceutical companies in the high-value oncology segment.
Shilpa Medicare Limited
Shilpa Medicare Limited has announced the successful conclusion of its postal ballot, with shareholders approving a special resolution to shift the company's registered office from one state to another. This change also necessitates an alteration to the situation clause of the Memorandum of Association. The company has submitted the scrutinizer's report and voting results to the exchanges, confirming the resolution was passed with the requisite majority.